In October 2017, Incyte entered into a global collaboration and license agreement with us in which they obtained exclusive worldwide rights for the development and commercialization of MGA012 (retifanlimab), an anti-PD-1 antibody, in all indications. In addition to receiving an upfront payment, MacroGenics is eligible to receive milestones and royalties and retains the right to develop its pipeline assets in combination with MGA012. Learn more
Collaborations have been a critical part of MacroGenics’ growth strategy and will continue to be an emphasis for our future growth strategy. To date, the company has developed significant alliances with leading pharmaceutical and biotechnology companies that enable us to drive our proprietary programs forward, while retaining significant value in the downstream potential of our partnered programs.
The company is actively exploring alliances that complement our expertise in biologics product development with important scientific, clinical and business capabilities. These alliances may incorporate our various technology platforms, product candidates and biologic product development capabilities.
Selected MacroGenics Collaboration Partners
In October 2022, we announced that Gilead entered into an exclusive option and collaboration agreement with us to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using our DART® platform, and two additional bispecific research programs. MacroGenics is responsible for the ongoing Phase 1 study for MGD024 during which Gilead may elect to exercise its option to license the program at predefined decision points. MacroGenics received an upfront payment and will be eligible to receive target nomination, option fees, and milestone payments. MacroGenics will also be eligible to receive royalties on worldwide net sales of MGD024 and products under the two research programs. Learn more
In 2018, we entered into multiple agreements with Provention Bio, Inc. pursuant to which we granted exclusive global rights for the purpose of developing and commercializing MGD010 (PRV-3279), a CD32B x CD79B DART molecule, for the treatment of autoimmune indications. In addition, Provention acquired our interest in teplizumab (TZIELD™), an anti-CD3 monoclonal antibody approved by the U.S. FDA in November 2022 as the first and only treatment to delay the onset of Stage 3 type 1 diabetes. We are eligible to receive up to $170 million in regulatory milestones, up to $225 million in commercial milestones as well as royalties on net sales of the product.
In November 2018, we announced that Zai Lab had entered into an exclusive collaboration and license agreement with us for regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for margetuximab, MGD013 and an undisclosed multi-specific TRIDENT™ molecule in preclinical development. Learn more
In June 2021, we announced that Zai Lab entered into an exclusive collaboration and license agreement with us involving up to four CD3- or CD47-based bispecific, immuno-oncology molecules. We received an upfront payment and equity investment at a premium. In addition, we are eligible to receive milestone payments and royalties on net sales in Zai Lab’s territories. Learn more
In December 2020, Janssen entered into a research collaboration and global license agreement with us to develop a preclinical bispecific molecule that incorporates MacroGenics’ proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Learn more
In November 2020, we announced that we had partnered with EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, to commercialize margetuximab in the United States. EVERSANA will utilize its internal capabilities to support sales and marketing, market access, channel management services, data and analytics, medical affairs, and other patient access-related services. EVERSANA and MacroGenics will equally share in funding EVERSANA’s commercialization expenses. EVERSANA will earn future revenue share payments which will be capped at 125% of their cumulative service fees. Learn more